Valuation : Natera, Inc.

Market Cap 47.03B 40.52B 38B 34.68B 65.34B 4,495B 65.55B 451B 176B 2,269B 177B 173B 7,523B P/E 2026 *
-238x
P/E 2027 * -37,937x
Enterprise Value 45.96B 39.6B 37.13B 33.9B 63.86B 4,393B 64.06B 441B 172B 2,217B 173B 169B 7,352B EV / Sales 2026 *
15.8x
EV / Sales 2027 * 13.1x
Free-Float
97.12%
Yield 2026 *
-
Yield 2027 * -
1 day-3.67%
1 week-1.74%
Current month+21.85%
1 month+29.36%
3 months+52.50%
6 months+56.83%
Current year+42.42%
1 week 321.59
Extreme 321.59
343.18
1 month 252.39
Extreme 252.39
343.18
Current year 181
Extreme 181
343.18
1 year 157.42
Extreme 157.425
343.18
3 years 36.9
Extreme 36.9
343.18
5 years 26.1
Extreme 26.1
343.18
10 years 7.35
Extreme 7.35
343.18
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Sell

Founder

-6,000 0.0042%
07/08/26 Sell

Founder

-2,000 0.0014%
07/08/26 Sell

Founder

-9,150 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%-1.74%+94.34%+487.75% 47.03B
-0.21%-0.37%+21.73%+57.89% 27.18B
-0.30%-4.93%-16.15%-37.78% 7.1B
-1.00%-2.88%+3.93%+134.99% 5.87B
-0.27%+1.95%+16.22%+76.62% 3.38B
-3.26%-0.84%-33.07%+1,921.90% 2.57B
-3.17%+6.30%+150.35%+30.70% 2.32B
+1.02%+1.02%+29.25%+25.80% 1.97B
-1.93%-12.54%-14.69%-54.48% 1.89B
-0.85%-9.64%+6.63%-14.44% 1.69B
Average -1.36%-1.51%+25.85%+262.89% 10.1B
Weighted average by Cap. -2.04%-1.46%+52.42%+299.37%

Financials

2026 *2027 *
Net sales 2.91B 2.5B 2.35B 2.14B 4.04B 278B 4.05B 27.85B 10.86B 140B 10.91B 10.67B 465B 3.48B 3B 2.81B 2.57B 4.84B 333B 4.85B 33.36B 13.02B 168B 13.07B 12.78B 557B
Net income -193M -166M -156M -142M -268M -18.44B -269M -1.85B -722M -9.31B -724M -709M -30.86B 9.13M 7.87M 7.37M 6.73M 12.68M 872M 12.72M 87.5M 34.14M 440M 34.27M 33.53M 1.46B
Net Debt -1.07B -920M -863M -788M -1.48B -102B -1.49B -10.24B -3.99B -51.53B -4.01B -3.92B -171B -1.36B -1.17B -1.1B -1.01B -1.89B -130B -1.9B -13.07B -5.1B -65.76B -5.12B -5.01B -218B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
28/08/26 $326.26 -3.67% 833,801
27/08/26 $338.70 +0.07% 731,371
26/08/26 $338.45 +0.52% 1,094,667
25/08/26 $336.71 +2.74% 1,733,153
24/08/26 $327.72 -1.30% 1,219,524
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
326.26USD
Average target price
336.74USD
Spread / Average Target
+3.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock